ARF6 and pulmonary arterial hypertension: We also demonstrate increased activity of CLIC4/Arf6 in ECFCs from idiopathic PAH patients and in lung tissues from Sugen/hypoxia mice and monocrotaline rats and show the effectiveness of CLIC4/Arf6 targeting in the treatment of the disease in 2 different preclinical models of PAH.